



Fact Sheet


Update: March 2010

Headquartered in Brussels, Belgium, UCB is a biopharmaceutical company dedicated to the research, development and commercialisation of innovative medicines with a focus on the diseases of the central nervous system (CNS) and immunology disorders. UCB is driven by a passionate desire to liberate families living with severe disease so that they can enjoy normal, everyday lives.


Employing more than 9 000 people in over 40 countries, UCB achieved revenue of € 3.1 billion in 2009.

UCB has Research and Development Centres of Excellence in Europe, the U.S. and Asia and invested € 674 million in R&D expenditure in 2009.

- Strong in-house capabilities and control of key steps in the value chain
- Extensive experience in preclinical and clinical development, regulatory affairs and managing international alliances
- Research organisation for scientific and medical breakthroughs through a highly collaborative approach which emphasises partnering with external centres of expertise



Lakelsha, living with epilepsy



Carrie, living with Crohn's disease

Pipeline overview: key projects



CNS		Phase I	Phase II	Phase III	Regulatory Status
Keppra® (<i>levetiracetam</i>)	Epilepsy - adjunctive therapy (Japan)				Filed
Neupro® (<i>rotigotine</i>)	Advanced Parkinson's disease (U.S.)				CRL ¹
Neupro® (<i>rotigotine</i>)	Restless legs syndrome (U.S.)				CRL ¹
Xyrem® (<i>sodium oxybate</i>)	Fibromyalgia				
<i>brivaracetam</i>	Epilepsy - adjunctive therapy				
Vimpat® (<i>lacosamide</i>)	Epilepsy - monotherapy (U.S.)				
Vimpat® (<i>lacosamide</i>)	Epilepsy - adjunctive therapy ²				
Vimpat® (<i>lacosamide</i>)	Epilepsy - adjunctive therapy PGTC ³				
UCB2892 (<i>H₃ antagonist</i>)	Central nervous system				
Immunology					
Cimzia® (<i>certolizumab pegol</i>)	Rheumatoid arthritis (Japan)				
Cimzia® (<i>certolizumab pegol</i>)	Ankylosing spondylitis				
Cimzia® (<i>certolizumab pegol</i>)	Psoriatic arthritis				
Cimzia® (<i>certolizumab pegol</i>)	Juvenile rheumatoid arthritis				
<i>epratuzumab</i>	Systemic lupus erythematosus				
CDP7851 (<i>anti-sclerostin</i>)	Post-menopausal osteoporosis				
CDP7851 (<i>anti-sclerostin</i>)	Fracture healing				
CDP6038 (<i>anti-IL 6</i>)	Autoimmune diseases				

- 1 Complete Response Letter
 2 Paediatric (2-17 years)
 3 Primary generalised tonic clonic

Major recent launches

- Cimzia® (*certolizumab pegol*) Rheumatoid arthritis (U.S.) – May 2009
- Cimzia® (*certolizumab pegol*) Rheumatoid arthritis (EU) – October 2009
- Neupro® (*rotigotine*) Restless legs syndrome (EU) – June 2009
- Vimpat® (*lacosamide*)[Ⓢ] Epilepsy – adjunctive therapy (U.S.) – June 2009

Net sales 2009: € 2 683 million



Multinational marketing and sales infrastructure:

- Established and specialist-focused
- Experienced marketer and well-positioned licensing partner
- More than 4 500 professionals worldwide
- Core geographies: Europe, U.S., Asia

Core product	Indications	€ million	Change act. rate
Cimzia® (<i>certolizumab pegol</i>)	Rheumatoid arthritis & Crohn's disease	75	n.s.
Vimpat® (<i>lacosamide</i>)	Epilepsy	46	n.s.
Neupro® (<i>rotigotine</i>)	Restless legs syndrome & Parkinson's disease	61	5%
Other product			
Kepra® (<i>levetiracetam</i>) ¹	Epilepsy	913	-28%
Zyrtec® (<i>cetirizine</i>)	Allergy	268	8%
Tussionex™ (<i>hydrocodone polistirex and chlorpheniramine polistirex</i>)	Anti-tussive	147	0%
Xyzal® (<i>levocetirizine</i>)	Allergy	132	-23%
<i>venlafaxine XR</i>	Depressive & social anxiety disorders	109	n.s.
Metadate™ CD / Equasym™ XL (<i>methylphenidate HCl</i>)	Attention deficit hyperactivity disorder (ADHD)	72	-6%
Nootropil® (<i>piracetam</i>)	Cognitive disorders	70	-25%
<i>omeprazole</i>	Gastrointestinal reflux	64	-14%
Other products		726	-16%
Total net sales 2009		2 683	-11%

1 Including Kepra® XR

Financials 2009

€ million	Actual 2009	Actual 2008	Change actual rate
Revenues	3 116	3 601	-13%
Recurring EBIT	453	531	-15%
Net profit ¹	513	42	n.s.
Adjusted net profit	226	270	-16%
Recurring EBITDA	698	733	-5%

1 After minority interest

Corporate information: www.ucb.com



Sten, living with restless legs syndrome

Founded	1928
Listing	Euronext Brussels
Index	Bel20
Ticker	UCB / UCB Bt.BR / UCB BB
Number of shares	183 365 052
Free float	49.8%

Richard Simpson
Senior Director Investor Relations
Phone: +32 2 559 9494
Richard.Simpson@ucb.com

Michael Tuck-Sherman
Investor Relations Manager
Phone: +32 2 559 9712
Michael.Tuck-Sherman@ucb.com

Antje Witte
VP Corporate Communication & Investor Relations
Phone: +32 2 559 9414
Antje.Witte@ucb.com

Nancy Nackaerts
Director External Communications
Phone: +32 2 559 9264
Nancy.Nackaerts@ucb.com